Under construction – not a live service
Sign in
CompletedNo phase

Osia 2 Pediatric Expansion Study

Key facts

Who runs it
Cochlear
Where
Cleveland, Houston, Minneapolis, Palo Alto, Philadelphia, Phoenix, and San Diego, United StatesSee the 7 sites
Trial code
Status
Completed
People taking part
50 people enrolled
Started
26 Jan 2022
Ended
14 Mar 2024
Type of study
Interventional
Treatments tested
  • Osia 2 System
Record updated
11 December 2024

Who can take part

Age
5 years to 11 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Subjects aged 5 to 11 years of age with the following audiometric criterion:; A conductive or mixed hearing loss and still can benefit from sound amplification. The pure tone average (PTA) bone conduction (BC) threshold (measured at 0.5, 1, 2, and 3 kHz) should be better than or equal to 55 dB HL. OR; A profound sensorineural hearing loss in one ear and normal hearing in the opposite ear (i.e., single-sided deafness or "SSD"). The pure tone average air conduction hearing thresholds of the hearing ear should be better than or equal to 20 dB HL (measured at 0.5, 1, 2, and 3 kHz)
  • Prior experience with amplified sound through properly fitted amplification device such as a hearing aid, a CROS device, or a bone conduction device on a softband or sound arc
  • Parent or legal guardian who is willing and able to provide written informed consent for the study participant; Note: Subjects may include individuals seeking new implantation unilaterally (in one ear) or individuals already implanted with a bone-anchored device seeking a second-side implant (sequential bilateral)

Who cannot take part

  • Insufficient bone quality or quantity to support implantation of both the BI300 Implant and the OSI200 Implant
  • Currently participating, or participated within the last 30 days, in another clinical investigation involving an investigational drug or device that could impact the safety or effectiveness of the Osia 2 system as determined by the investigator
  • Chronic or non-revisable vestibular or balance disorders that could prevent benefit from the device, as determined by the investigator
  • Evidence of conditions that would prevent speech recognition improvement as determined by the investigator
  • Skin or scalp conditions that may preclude attachment of the Sound Processor or that may interfere with the use of the Sound Processor
  • Abnormally progressive hearing loss
  • Evidence that hearing loss is bilateral retro cochlear or bilateral central origin
  • Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator
  • Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as a spouse, parent, child, or sibling
  • Cochlear employees or employees of Contract Research Organizations or contractors engaged by Cochlear for the purposes of this investigation
  • Individuals undergoing simultaneous single-stage aural atresia or microtia repair due to the increased risk of skin complications associated with ear reconstruction

Where in United States

  • University Hospitals Cleveland Medical Center*Cleveland, United StatesNo longer taking part
  • Texas Children's HospitalHouston, United StatesNo longer taking part
  • Children's MinnesotaMinneapolis, United StatesNo longer taking part
  • Stanford UniversityPalo Alto, United StatesNo longer taking part
  • Children's Hospital of PhiladelphiaPhiladelphia, United StatesNo longer taking part
  • Barrow Neurological InstitutePhoenix, United StatesNo longer taking part
  • Rady Children's HospitalSan Diego, United StatesNo longer taking part

About the trial

What the trial wants to find out

The CochlearTM Osia®2 System was cleared by the Food and Drug Administration November 15, 2019 (K191921) for individuals aged 12 years and older who present with conductive or mixed hearing loss (up to 55 dB HL) or single-sided-deafness (SSD).Published and unpublished data suggest significant pre to postoperative benefit and minimal risk in both children and adults who have received the Osia system. Thus the objective of this study is to examine the safety and effectiveness of the Cochlear Osia 2 system in a group of pediatric subjects aged 5 to 11 years who suffer from conductive or mixed hearing loss (up to 55 dB HL), or single-sided-deafness (SSD) with the intent of expanding the indications for use.

The group in the trial

  • To demonstrate the safety of the Osia 2 System in a pediatric population aged 5 - 11 years.Treatment being tested

    Treatment: Osia 2 System

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Pivotal, Prospective, Multi-center, Open-label Study Evaluating the Safety and Effectiveness of the CochlearTM Osia® 2 System in a Pediatric Population.
Record updated
11 December 2024